Why clinical development’s next AI bottleneck is not the model, but the system around it.
|Articles|July 14, 2023
NEXT Oncology Joins Proxima Clinical Research Early Phase Oncology Network
The addition of NEXT Oncology investigators expands Proxima CRO’s Phase I clinical trials network.
Advertisement
CRO Proxima Clinical Research is expanding its Early Phase Oncology Network (EPON) with the addition of NEXT Oncology, a Phase I clinical trial treatment center. Serving patients out of Virginia, Austin, Dallas, San Antonio, and abroad in Barcelona and Madrid, NEXT Oncology is an early adopter within the Proxima CRO EPON.
Launched in November 2017 and headquartered in the Texas Medical Center Innovation Center in Houston, Proxima CRO has a vast network of cancer research clinics in the United States. Its intent is to advance conceptual development and translational applications, as well serve as a conduit to innovative treatment modalities in investigational cancer therapies.
Reference: NEXT Oncology joins Proxima Clinical Research Early Phase Oncology Network to Advance Investigational Cancer Therapies. HOUSTON, Texas– July 10, 2023.
Advertisement
Related to this article
In today's ACT Brief, we examine FDA's expedited pathway for first-in-human trials, why operating model design matters more than sourcing strategy, and how early readiness signals predict trial risk.
FDA Opens Applications for Expedited IND Pilot Designed to Accelerate First-in-Human Trial Timelines
The pilot pairs drug sponsors with qualified research institutions to compress the path from drug identification to first-in-human study through rolling submission review and earlier coordination of institutional review board and site activation activities.
A Syneos Health-announced study from Tufts Center for the Study of Drug Development finds no single sourcing model consistently outperforms others, pointing instead to vendor coordination, governance, and fit-for-purpose design as the real performance drivers.
Regulatory expectations for patient input in drug development have shifted from aspiration to documented methodology across three major jurisdictions.
This episode of The Human Side of Clinical Trials, hosted by Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., explores why training completion metrics like attendance and quiz scores fail to capture true study readiness, and how measuring both competence and confidence can reveal trial risks before enrollment even begins.
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, outlines what it takes to move beyond transactional engagement and treat patient advocacy organizations as long-term partners in the science and the care.
In today's ACT Brief, we examine what families with rare epilepsy teach about trial feasibility, how preclinical CRO partnerships are evolving beyond transactional services, and why cortisol dysregulation limits GLP-1 effectiveness in diabetes.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Benchmarking Study Finds Clinical Trial Performance Is Shaped by Operating Model Design, Not Sourcing Strategy
2
The Execution Gap: Why Clinical Trial Infrastructure Has to Be Built Before AI Can Deliver
3
Operationalizing the Patient Voice: Converging U.S., EU, and UK Requirements and the Role of Real-World Patient-Reported Data
4
FDA Opens Applications for Expedited IND Pilot Designed to Accelerate First-in-Human Trial Timelines
5